Ignite Creation Date:
2024-05-06 @ 12:12 PM
Last Modification Date:
2024-10-26 @ 12:55 PM
Study NCT ID:
NCT03704077
Status:
WITHDRAWN
Last Update Posted:
2020-05-19
First Post:
2018-10-09
Brief Title:
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-10-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2022-02-27
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2018-10-09
First Submit QC Date:
October 9 2018
Study First Post Date:
2018-10-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-05-17
Last Update Post Date:
2020-05-19
Last Update Post Date Type:
ACTUAL